text:
Sickle cell disease
From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sickle cell disease
Synonyms
Sickle cell disorder
Figure (A) shows normal red blood cells flowing freely through veins. The inset shows a cross section of a normal red blood cell with normal haemoglobin. Figure (B) shows abnormal, sickled red blood cells sticking at the branching point in a vein. The inset image shows a cross-section of a sickle cell with long polymerized sickle haemoglobin (HbS) strands stretching and distorting the cell shape.
Specialty
Hematology
Symptoms
Attacks of pain, anemia, swelling in the hands and feet, bacterial infections, stroke[1]
Complications
Chronic pain[2]
Usual onset
5–6 months of age[1]
Causes
Genetic[3]
Diagnostic method
Blood test[4]
Treatment
Vaccination, antibiotics, high fluid intake, folic acid supplementation. pain medication, blood transfusions[5][6]
Prognosis
Life expectancy 40–60 years (developed world)[2]
Frequency
4.4 million (2015)[7]
Deaths
114,800 (2015)[8]
Sickle cell disease (SCD) is a group of blood disorders typically inherited from a person's parents.[2] The most common type is known as sickle cell anaemia (SCA).[2] It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells.[2] This leads to a rigid, sickle-like shape under certain circumstances.[2] Problems in sickle cell disease typically begin around 5 to 6 months of age.[1] A number of health problems may develop, such as attacks of pain ("sickle cell crisis"), anemia, swelling in the hands and feet, bacterial infections and stroke.[1] Long-term pain may develop as people get older.[2] The average life expectancy in the developed world is 40 to 60 years.[2]
Sickle cell disease occurs when a person inherits two abnormal copies of the haemoglobin gene, one from each parent.[3] This gene occurs in chromosome 11.[9] Several subtypes exist, depending on the exact mutation in each haemoglobin gene.[2] An attack can be set off by temperature changes, stress, dehydration and high altitude.[1] A person with a single abnormal copy does not usually have symptoms and is said to have sickle cell trait.[3] Such people are also referred to as carriers.[5] Diagnosis is by a blood test, and some countries test all babies at birth for the disease.[4] Diagnosis is also possible during pregnancy.[4]
The care of people with sickle cell disease may include infection prevention with vaccination and antibiotics, high fluid intake, folic acid supplementation and pain medication.[5][6] Other measures may include blood transfusion and the medication hydroxycarbamide (hydroxyurea).[6] A small percentage of people can be cured by a transplant of bone marrow cells.[2]
As of 2015, about 4.4 million people have sickle cell disease, while an additional 43 million have sickle cell trait.[7][10] About 80% of sickle cell disease cases are believed to occur in Sub-Saharan Africa.[11] It also occurs relatively frequently in parts of India, the Arabian Peninsula and among people of African origin living in other parts of the world.[12] In 2015, it resulted in about 114,800 deaths.[8] The condition was first described in the medical literature by the American physician James B. Herrick in 1910.[13][14] In 1949, the genetic transmission was determined by E. A. Beet and J. V. Neel.[14] In 1954, the protective effect against malaria of sickle cell trait was described.[14]
Contents
1 Signs and symptoms
1.1 Sickle cell crisis
1.2 Vaso-occlusive crisis
1.3 Splenic sequestration crisis
1.4 Acute chest syndrome
1.5 Aplastic crisis
1.6 Haemolytic crisis
1.7 Other
2 Genetics
3 Pathophysiology
4 Diagnosis
5 Management
5.1 Folic acid and penicillin
5.2 Malaria prevention
5.3 Vaso-occlusive crisis
5.4 Acute chest crisis
5.5 Hydroxyurea
5.6 Blood transfusion
5.7 Bone marrow transplant
5.8 Avascular necrosis
5.9 Psychological therapies
6 Prognosis
6.1 Complications
7 Epidemiology
7.1 Africa
7.2 United States
7.3 France
7.4 United Kingdom
7.5 Middle East
7.6 India and Nepal
7.7 Caribbean Islands
8 History
9 Society and culture
9.1 U.S. Social Security
10 Research
10.1 Umbilical cord blood transplant
10.2 Gene therapy
11 Notes
12 References
13 Further reading
14 External links
Signs and symptoms[edit]
Sickle cell anaemia
Sickle cells in human blood: both normal red blood cells and sickle-shaped cells are present.
Normal blood cells next to a sickle blood cell, colored scanning electron microscope image
Signs of sickle cell disease usually begin in early childhood. The severity of symptoms can vary from person to person.[15] Sickle cell disease may lead to various acute and chronic complications, several of which have a high mortality rate.[16]
Sickle cell crisis[edit]
The terms "sickle cell crisis" or "sickling crisis" may be used to describe several independent acute conditions occurring in patients with SCD. SCD results in anaemia and crises that could be of many types including the vaso-occlusive crisis, aplastic crisis, sequestration crisis, haemolytic crisis, and others. Most episodes of sickle cell crises last between five and seven days.[17] "Although infection, dehydration, and acidosis (all of which favor sickling) can act as triggers, in most instances, no predisposing cause is identified."[18]
Vaso-occlusive crisis[edit]
The vaso-occlusive crisis is caused by sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ resulting in ischaemia, pain, necrosis, and often organ damage. The frequency, severity, and duration of these crises vary considerably. Painful crises are treated with hydration, analgesics, and blood transfusion; pain management requires opioid administration at regular intervals until the crisis has settled. For milder crises, a subgroup of patients manage on nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac or naproxen. For more severe crises, most patients require inpatient management for intravenous opioids; patient-controlled analgesia devices are commonly used in this setting. Vaso-occlusive crisis involving organs such as the penis[19] or lungs are considered an emergency and treated with red-blood cell transfusions. Incentive spirometry, a technique to encourage deep breathing to minimise the development of atelectasis, is recommended.[20]
Splenic sequestration crisis[edit]
Because of its narrow vessels and function in clearing defective red blood cells, the spleen is frequently affected.[21] It is usually infarcted before the end of childhood in individuals suffering from sickle cell anaemia. This spleen damage increases the risk of infection from encapsulated organisms;[22][23] preventive antibiotics and vaccinations are recommended for those lacking proper spleen function.
Splenic sequestration crises are acute, painful enlargements of the spleen, caused by intrasplenic trapping of red cells and resulting in a precipitous fall in haemoglobin levels with the potential for hypovolemic shock. Sequestration crises are considered an emergency. If not treated, patients may die within 1–2 hours due to circulatory failure. Management is supportive, sometimes with blood transfusion. These crises are transient, they continue for 3–4 hours and may last for one day.[24]
Acute chest syndrome[edit]
Acute chest syndrome (ACS) is defined by at least two of the following signs or symptoms: chest pain, fever, pulmonary infiltrate or focal abnormality, respiratory symptoms, or hypoxemia.[25] It is the second-most common complication and it accounts for about 25% of deaths in patients with SCD, majority of cases present with vaso-occlusive crises then they develop ACS.[26][27] Nevertheless, about 80% of patients have vaso-occlusive crises during ACS.
Aplastic crisis[edit]
Aplastic crises are acute worsenings of the patient's baseline anaemia, producing pale appearance, fast heart rate, and fatigue. This crisis is normally triggered by parvovirus B19, which directly affects production of red blood cells by invading the red cell precursors and multiplying in and destroying them.[28] Parvovirus infection almost completely prevents red blood cell production for two to three days. In normal individuals, this is of little consequence, but the shortened red cell life of SCD patients results in an abrupt, life-threatening situation. Reticulocyte counts drop dramatically during the disease (causing reticulocytopenia), and the rapid turnover of red cells leads to the drop in haemoglobin. This crisis takes 4 days to one week to disappear. Most patients can be managed supportively; some need blood transfusion.[29]
Haemolytic crisis[edit]
Haemolytic crises are acute accelerated drops in haemoglobin level. The red blood cells break down at a faster rate. This is particularly common in patients with coexistent G6PD deficiency.[30] Management is supportive, sometimes with blood transfusions.[20]
Other[edit]
One of the earliest clinical manifestations is dactylitis, presenting as early as six months of age, and may occur in children with sickle cell trait.[31] The crisis can last up to a month.[32] Another recognised type of sickle crisis, acute chest syndrome, is characterised by fever, chest pain, difficulty breathing, and pulmonary infiltrate on a chest X-ray. Given that pneumonia and sickling in the lung can both produce these symptoms, the patient is treated for both conditions.[33] It can be triggered by painful crisis, respiratory infection, bone-marrow embolisation, or possibly by atelectasis, opiate administration, or surgery.[citation needed] Hematopoietic ulcers may also occur.[34]
Genetics[edit]
Sickle cell disease is inherited in an autosomal recessive pattern.
Distribution of the sickle cell trait, shown in pink and purple
Historical distribution of malaria (no longer endemic in Europe), shown in green
Modern distribution of malaria
Normally, humans have haemoglobin A, which consists of two alpha and two beta chains, haemoglobin A2, which consists of two alpha and two delta chains, and haemoglobin F, consisting of two alpha and two gamma chains in their bodies. Out of these three types, haemoglobin F dominates until about 6 weeks of age. Afterwards, haemoglobin A dominates throughout life.[citation needed] In people diagnosed with sickle cell disease, at least one of the β-globin subunits in haemoglobin A is replaced with what's known as haemoglobin S. In sickle cell anaemia, a common form of sickle cell disease, haemoglobin S replaces both β-globin subunits in the haemoglobin.[15]
Sickle cell conditions have an autosomal recessive pattern of inheritance from parents. The types of haemoglobin a person makes in the red blood cells depend on what haemoglobin genes are inherited from her or his parents. If one parent has sickle cell anaemia and the other has sickle cell trait, then the child has a 50% chance of having sickle cell disease and a 50% chance of having sickle cell trait. When both parents have sickle cell trait, a child has a 25% chance of sickle cell disease, 25% do not carry any sickle cell alleles, and 50% have the heterozygous condition.[35]
Sickle cell gene mutation probably arose spontaneously in different geographic areas, as suggested by restriction endonuclease analysis. These variants are known as Cameroon, Senegal, Benin, Bantu, and Saudi-Asian. Their clinical importance is because some are associated with higher HbF levels, e.g., Senegal and Saudi-Asian variants, and tend to have milder disease.[36]
The gene defect is a known mutation of a single nucleotide (see single-nucleotide polymorphism – SNP) (GAG codon changing to GTG) of the β-globin gene, which results in glutamic acid (E/Glu) being substituted by valine (V/Val) at position 6.[37][note 1] Haemoglobin S with this mutation is referred to as HbS, as opposed to the normal adult HbA. This is normally a benign mutation, causing no apparent effects on the secondary, tertiary, or quaternary structures of haemoglobin in conditions of normal oxygen concentration. What it does allow for, under conditions of low oxygen concentration, is the polymerization of the HbS itself. The deoxy form of haemoglobin exposes a hydrophobic patch on the protein between the E and F helices (Phe 85, Leu 88). The hydrophobic side chain of the valine residue at position 6 of the beta chain in haemoglobin is able to associate with the hydrophobic patch, causing HbS molecules to aggregate and form fibrous precipitates.[38]
In people heterozygous for HbS (carriers of sickling haemoglobin), the polymerisation problems are minor, because the normal allele is able to produce half of the haemoglobin. In people homozygous for HbS, the presence of long-chain polymers of HbS distort the shape of the red blood cell from a smooth doughnut-like shape to ragged and full of spikes, making it fragile and susceptible to breaking within capillaries. Carriers have symptoms only if they are deprived of oxygen (for example, while climbing a mountain) or while severely dehydrated.
HBB gene (responsible for sickle cell anaemia) is located on the short (p) arm of chromosome 11 at position 15.5.
The allele responsible for sickle cell anaemia can be found on the short arm of chromosome 11, more specifically 11p15.5. A person who receives the defective gene from both father and mother develops the disease; a person who receives one defective and one healthy allele remains healthy, but can pass on the disease and is known as a carrier or heterozygote. Heterozygotes are still able to contract malaria, but their symptoms are generally less severe.[39]
Due to the adaptive advantage of the heterozygote, the disease is still prevalent, especially among people with recent ancestry in malaria-stricken areas, such as Africa, the Mediterranean, India, and the Middle East.[40] Malaria was historically endemic to southern Europe, but it was declared eradicated in the mid-20th century, with the exception of rare sporadic cases.[41]
The malaria parasite has a complex lifecycle and spends part of it in red blood cells. In a carrier, the presence of the malaria parasite causes the red blood cells with defective haemoglobin to rupture prematurely, making the Plasmodium parasite unable to reproduce. Further, the polymerization of Hb affects the ability of the parasite to digest Hb in the first place. Therefore, in areas where malaria is a problem, people's chances of survival actually increase if they carry sickle cell trait (selection for the heterozygote).
In the United States, with no endemic malaria, the prevalence of sickle cell anaemia among African Americans is lower (about 0.25%) than in West Africa (about 4.0%) and is falling. Without endemic malaria, the sickle cell mutation is purely disadvantageous and tends to decline in the affected population by natural selection, and now artificially through prenatal genetic screening. However, the African American community descends from a significant admixture of several African and non-African ethnic groups and also represents the descendants of survivors of slavery and the slave trade. Thus, a lower degree of endogamy and, particularly, abnormally high health-selective pressure through slavery may be the most plausible explanations for the lower prevalence of sickle cell anaemia (and, possibly, other genetic diseases) among African Americans compared to West Africans. Another factor that limits the spread of sickle cell genes in North America is the absence of cultural proclivities to polygamy, which allows affected males to continue to seek unaffected children with multiple partners.[42]
Pathophysiology[edit]
Scanning electron micrograph showing a mixture of red blood cells, some with round normal morphology, some with mild sickling showing elongation and bending
The loss of red blood cell elasticity is central to the pathophysiology of sickle cell disease. Normal red blood cells are quite elastic, which allows the cells to deform to pass through capillaries. In sickle cell disease, low oxygen tension promotes red blood cell sickling and repeated episodes of sickling damage the cell membrane and decrease the cell's elasticity. These cells fail to return to normal shape when normal oxygen tension is restored. As a consequence, these rigid blood cells are unable to deform as they pass through narrow capillaries, leading to vessel occlusion and ischaemia.
The actual anaemia of the illness is caused by haemolysis, the destruction of the red cells, because of their shape. Although the bone marrow attempts to compensate by creating new red cells, it does not match the rate of destruction.[43] Healthy red blood cells typically function for 90–120 days, but sickled cells only last 10–20 days.[44]
Diagnosis[edit]
In HbS, the complete blood count reveals haemoglobin levels in the range of 6–8 g/dl with a high reticulocyte count (as the bone marrow compensates for the destruction of sickled cells by producing more red blood cells). In other forms of sickle cell disease, Hb levels tend to be higher. A blood film may show features of hyposplenism (target cells and Howell-Jolly bodies).
Sickling of the red blood cells, on a blood film, can be induced by the addition of sodium metabisulfite. The presence of sickle haemoglobin can also be demonstrated with the "sickle solubility test". A mixture of haemoglobin S (Hb S) in a reducing solution (such as sodium dithionite) gives a turbid appearance, whereas normal Hb gives a clear solution.
Abnormal haemoglobin forms can be detected on haemoglobin electrophoresis, a form of gel electrophoresis on which the various types of haemoglobin move at varying speeds. Sickle cell haemoglobin (HgbS) and haemoglobin C with sickling (HgbSC)—the two most common forms—can be identified from there. The diagnosis can be confirmed with high-performance liquid chromatography. Genetic testing is rarely performed, as other investigations are highly specific for HbS and HbC.[45]
An acute sickle cell crisis is often precipitated by infection. Therefore, a urinalysis to detect an occult urinary tract infection, and chest X-ray to look for occult pneumonia should be routinely performed.[46]
People who are known carriers of the disease often undergo genetic counseling before they have a child. A test to see if an unborn child has the disease takes either a blood sample from the fetus or a sample of amniotic fluid. Since taking a blood sample from a fetus has greater risks, the latter test is usually used. Neonatal screening provides not only a method of early detection for individuals with sickle cell disease, but also allows for identification of the groups of people that carry the sickle cell trait.[47]
Management[edit]
Further information: Pain management in children
Treatment involves a number of measures. L-glutamine use was supported by the FDA starting at the age of 5 as it decreases complications.[48]
Folic acid and penicillin[edit]
From birth to five years of age, penicillin daily, due to the immature immune system that makes them more prone to early childhood illnesses is recommended.[49] Dietary supplementation of folic acid had been previously recommended by the WHO.[5] A 2016 Cochrane review of its use found "the effect of supplementation on anaemia and any symptoms of anaemia remains unclear" due to a lack of medical evidence.[50]
Malaria prevention[edit]
The protective effect of sickle cell trait does not apply to people with sickle cell disease; in fact, they are more vulnerable to malaria, since the most common cause of painful crises in malarial countries is infection with malaria. It has therefore been recommended that people with sickle cell disease living in malarial countries should receive anti-malarial chemoprophylaxis for life.[51]
Vaso-occlusive crisis[edit]
Most people with sickle cell disease have intensely painful episodes called vaso-occlusive crises. However, the frequency, severity, and duration of these crises vary tremendously. Painful crises are treated symptomatically with pain medications; pain management requires opioid administration at regular intervals until the crisis has settled. For milder crises, a subgroup of patients manage on NSAIDs (such as diclofenac or naproxen). For more severe crises, most patients require inpatient management for intravenous opioids; patient-controlled analgesia (PCA) devices are commonly used in this setting. Diphenhydramine is also an effective agent that doctors frequently prescribe to help control itching associated with the use of opioids.[citation needed]
Acute chest crisis[edit]
Management is similar to vaso-occlusive crisis, with the addition of antibiotics (usually a quinolone or macrolide, since cell wall-deficient ["atypical"] bacteria are thought to contribute to the syndrome),[52] oxygen supplementation for hypoxia, and close observation. Should the pulmonary infiltrate worsen or the oxygen requirements increase, simple blood transfusion or exchange transfusion is indicated. The latter involves the exchange of a significant portion of the person's red cell mass for normal red cells, which decreases the percent of haemoglobin S in the patient's blood. The patient with suspected acute chest syndrome should be admitted to the hospital with worsening A-a gradient an indication for ICU admission.[25]
Hydroxyurea[edit]
The first approved drug for the causative treatment of sickle cell anaemia, hydroxyurea, was shown to decrease the number and severity of attacks in a study in 1995[53] and shown to possibly increase survival time in a study in 2003.[54] This is achieved, in part, by reactivating fetal haemoglobin production in place of the haemoglobin S that causes sickle cell anaemia. Hydroxyurea had previously been used as a chemotherapy agent, and there is some concern that long-term use may be harmful, but this risk has been shown to be either absent or very small and it is likely that the benefits outweigh the risks.[16][55]
Blood transfusion[edit]
Blood transfusions are often used in the management of sickle cell disease in acute cases and to prevent complications by decreasing the number of red blood cells (RBC) that can sickle by adding normal red blood cells.[56] In children preventative red blood cell (RBC) transfusion therapy has been shown to reduce the risk of first stroke or silent stroke when transcranial Doppler (TCD) ultrasonography shows abnormal cerebral blood flow.[6] In those who have sustained a prior stroke event it also reduces the risk of recurrent stroke and additional silent strokes.[57][58]
Bone marrow transplant[edit]
Bone marrow transplants have proven effective in children. Bone marrow transplants are the only known cure for SCD.[59] However, bone marrow transplants are difficult to obtain because of the specific HLA typing necessary. Ideally, a close relative (allogeneic) would donate the bone marrow necessary for transplantation.
Avascular necrosis[edit]
When treating avascular necrosis of the bone in people with sickle cell disease, the aim of treatment is to reduce or stop the pain and maintain joint mobility.[60] Current treatment options are to rest the joint, physical therapy, pain relief medicine, joint replacement surgery, or bone grafting.[60] High quality randomized controlled trials are needed to assess the most effective treatment option and determine if a combination of physical therapy and surgery are more effective than physical therapy alone.[60]
Psychological therapies[edit]
Psychological therapies such as patient education, cognitive therapy, behavioural therapy and psychodynamic psychotherapy, that aim to complement current medical treatments, require further research to determine their effectiveness.[21]
Prognosis[edit]
About 90% of people survive to age 20, and close to 50% survive beyond age 50.[61] In 2001, according to one study performed in Jamaica, the estimated mean survival for people with sickle cell was 53 years old for men and 58 years old for women with homozygous SCD.[62] The specific life expectancy in much of the developing world is unknown.[63]
Complications[edit]
Sickle cell anaemia can lead to various complications, including:
Increased risk of severe bacterial infections due to loss of functioning spleen tissue (and comparable to the risk of infections after having the spleen removed surgically). These infections are typically caused by encapsulated organisms such as Streptococcus pneumoniae and Haemophilus influenzae. Daily penicillin prophylaxis is the most commonly used treatment during childhood, with some haematologists continuing treatment indefinitely. Patients benefit today from routine vaccination for S. pneumoniae.[64]
Stroke, which can result from a progressive narrowing of blood vessels, prevents oxygen from reaching the brain. Cerebral infarction occurs in children and cerebral haemorrhage in adults.[citation needed]
Silent stroke causes no immediate symptoms, but is associated with damage to the brain. Silent stroke is probably five times as common as symptomatic stroke. About 10–15% of children with SCD suffer strokes, with silent strokes predominating in the younger patients.[65][66]
Cholelithiasis (gallstones) and cholecystitis may result from excessive bilirubin production and precipitation due to prolonged haemolysis.
Avascular necrosis (aseptic bone necrosis) of the hip and other major joints may occur as a result of ischaemia.[60]
Decreased immune reactions due to hyposplenism (malfunctioning of the spleen)[67]
Priapism and infarction of the penis[68]
Osteomyelitis (bacterial bone infection), the most common cause of osteomyelitis in SCD is Salmonella (especially the atypical serotypes Salmonella typhimurium, Salmonella enteritidis, Salmonella choleraesuis and Salmonella paratyphi B), followed by Staphylococcus aureus and Gram-negative enteric bacilli perhaps because intravascular sickling of the bowel leads to patchy ischaemic infarction.[69]
Acute papillary necrosis in the kidneys
Leg ulcers[70]
In eyes, background retinopathy, proliferative retinopathy, vitreous haemorrhages, and retinal detachments can result in blindness.[71] Regular annual eye checks are recommended.
During pregnancy, intrauterine growth retardation, spontaneous abortion, and pre-eclampsia
Chronic pain: Even in the absence of acute vaso-occlusive pain, many patients have unreported chronic pain.[72]
Pulmonary hypertension (increased pressure on the pulmonary artery) can lead to strain on the right ventricle and a risk of heart failure; typical symptoms are shortness of breath, decreased exercise tolerance, and episodes of syncope.[citation needed] 21% of children and 30% of adults have evidence of pulmonary hypertension when tested; this is associated with reduced walking distance and increased mortality.[73]
Chronic kidney failure due to sickle-cell nephropathy manifests itself with hypertension, protein loss in the urine, loss of red blood cells in urine and worsened anaemia. If it progresses to end-stage renal failure, it carries a poor prognosis.[74]
Epidemiology[edit]
The highest frequency of sickle cell disease is found in tropical regions, particularly sub-Saharan Africa, tribal regions of India and the Middle East.[75] Migration of substantial populations from these high prevalence areas to low prevalence countries in Europe has dramatically increased in recent decades and in some European countries sickle cell disease has now overtaken more familiar genetic conditions such as haemophilia and cystic fibrosis.[76] In 2015, it resulted in about 114,800 deaths.[8]
Sickle cell disease occurs more commonly among people whose ancestors lived in tropical and sub-tropical sub-Saharan regions where malaria is or was common. Where malaria is common, carrying a single sickle cell allele (trait) confers a heterozygote advantage: humans with one of the two alleles of sickle cell disease show less severe symptoms when infected with malaria.[77]
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.[78]
Africa[edit]
Three-quarters of sickle cell cases occur in Africa. A recent WHO report estimated that around 2% of newborns in Nigeria were affected by sickle cell anaemia, giving a total of 150,000 affected children born every year in Nigeria alone. The carrier frequency ranges between 10% and 40% across equatorial Africa, decreasing to 1–2% on the north African coast and <1% in South Africa.[79] There have been studies in Africa that show a significant decrease in infant mortality rate, ages 2–16 months, because of the sickle cell trait. This happened in predominant areas of malarial cases.[80]
United States[edit]
The number of people with the disease in the United States is approximately 1 in 5,000, mostly affecting Americans of sub-Saharan African descent, according to the National Institutes of Health.[81] In the United States, about one out of 500 African-American children and one in every 36,000 Hispanic-American children have sickle cell anaemia.[82] It is estimated that sickle cell disease affects 90,000 Americans.[83] Most infants with SCD born in the United States are now identified by routine neonatal screening. As of 2016 all 50 states include screening for sickle cell disease as part of their newborn screen.[84] Patient advocates for sickle cell disease have complained that it gets less government and private research funding than similar rare diseases like cystic fibrosis, with researcher Elliott Vichinsky saying this shows racial discrimination or the role of wealth in health care advocacy.[85]
France[edit]
As a result of population growth in African-Caribbean regions of overseas France and immigration from North and sub-Saharan Africa to mainland France, sickle cell disease has become a major health problem in France.[86] SCD has become the most common genetic disease in the country, with an overall birth prevalence of 1/2,415 in Metropolitan France, ahead of phenylketonuria (1/10,862), congenital hypothyroidism (1/3,132), congenital adrenal hyperplasia (1/19,008) and cystic fibrosis (1/5,014) for the same reference period.
Since 2000, neonatal screening of SCD has been performed at national level for all newborns defined as being "at risk" for SCD based on ethnic origin (defined as those born to parents originating from sub-Saharan Africa, North Africa, the Mediterranean area (South Italy, Greece and Turkey), the Arabic peninsula, the French overseas islands and the Indian subcontinent).[87]
United Kingdom[edit]
In the United Kingdom, it is thought that between 12,000 and 15,000 people have sickle cell disease [88] with an estimate of 250,000 carriers of the condition in England alone. As the number of carriers is only estimated, all newborn babies in the UK receive a routine blood test to screen for the condition.[89] Due to many adults in high-risk groups not knowing if they are carriers, pregnant women and both partners in a couple are offered screening so they can get counselling if they have the sickle cell trait.[90] In addition blood donors from those in high-risk groups are also screened to confirm whether they are carriers and whether their blood filters properly.[91] Donors who are found to be carriers are then informed and their blood, while often used for those of the same ethnic group, is not used for those with sickle cell disease who require a blood transfusion.[92]
Middle East[edit]
In Saudi Arabia, about 4.2% of the population carry the sickle cell trait and 0.26% have sickle cell disease. The highest prevalence is in the Eastern province where approximately 17% of the population carry the gene and 1.2% have sickle cell disease.[93] In 2005, Saudi Arabia introduced a mandatory pre-marital test including HB electrophoresis which aimed to decrease the incidence of SCD and thalassemia.[94]
In Bahrain a study published in 1998 that covered about 56,000 people in hospitals in Bahrain found that 2% of newborns have sickle cell disease, 18% of the surveyed people have the sickle cell trait, and 24% were carriers of the gene mutation causing the disease.[95] The country began screening of all pregnant women in 1992 and newborns started being tested if the mother was a carrier. In 2004, a law was passed requiring couples planning to get married to undergo free premarital counseling. These programs were accompanied by public education campaigns.[96]
India and Nepal[edit]
Sickle cell disease is common in ethnic groups of central India who share a genetic linkage with African communities,[97] where the prevalence has ranged from 9.4 to 22.2% in endemic areas of Madhya Pradesh, Rajasthan and Chhattisgarh.[98] It is also endemic among Tharu people of Nepal and India; however, they have a sevenfold lower incidence of malaria despite living in a malaria infested zone.[99]
Caribbean Islands[edit]
In Jamaica, 10% of the population carries the sickle cell gene, making it the most prevalent genetic disorder in the country.[100]
History[edit]
The first modern report of sickle cell disease may have been in 1846, where the autopsy of an executed runaway slave was discussed; the key findings was the absence of the spleen.[101][102] There were also reports amongst African slaves in the United States exhibiting resistance to malaria but being prone to leg ulcers.[102] The abnormal characteristics of the red blood cells, which later lent their name to the condition, was first described by Ernest E. Irons (1877–1959), intern to the Chicago cardiologist and professor of medicine James B. Herrick (1861–1954), in 1910. Irons saw "peculiar elongated and sickle-shaped" cells in the blood of a man named Walter Clement Noel, a 20-year-old first-year dental student from Grenada. Noel had been admitted to the Chicago Presbyterian Hospital in December 1904 suffering from anaemia.[13][103] Noel was readmitted several times over the next three years for "muscular rheumatism" and "bilious attacks" but completed his studies and returned to the capital of Grenada (St. George's) to practice dentistry. He died of pneumonia in 1916 and is buried in the Catholic cemetery at Sauteurs in the north of Grenada.[13][14] Shortly after the report by Herrick, another case appeared in the Virginia Medical Semi-Monthly with the same title, "Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in a Case of Severe Anemia."[104] This article is based on a patient admitted to the University of Virginia Hospital on November 15, 1910.[105] In the later description by Verne Mason in 1922, the name "sickle cell anemia" is first used.[14][106] Childhood problems related to sickle cells disease were not reported until the 1930s, despite the fact that this cannot have been uncommon in African-American populations.[102]
The Memphis physician Lemuel Diggs, a prolific researcher into sickle cell disease, first introduced the distinction between sickle cell disease and trait in 1933, although it took until 1949 until the genetic characteristics were elucidated by James V. Neel and E.A. Beet.[14] 1949 was the year when Linus Pauling described the unusual chemical behaviour of haemoglobin S, and attributed this to an abnormality in the molecule itself.[14][107] The actual molecular change in HbS was described in the late 1950s by Vernon Ingram.[14] The late 1940s and early 1950s saw further understanding in the link between malaria and sickle cell disease. In 1954, the introduction of haemoglobin electrophoresis allowed the discovery of particular subtypes, such as HbSC disease.[14]
Large scale natural history studies and further intervention studies were introduced in the 1970s and 1980s, leading to widespread use of prophylaxis against pneumococcal infections amongst other interventions. Bill Cosby's Emmy-winning 1972 TV movie, To All My Friends on Shore, depicted the story of the parents of a child suffering from sickle cell disease.[108] The 1990s saw the development of hydroxycarbamide, and reports of cure through bone marrow transplantation appeared in 2007.[14]
Some old texts refer to it as drepanocytosis.[109]
Society and culture[edit]
U.S. Social Security[edit]
Effective September 15, 2017, the U.S. Social Security Administration issued a Policy Interpretation Ruling providing background information on sickle cell disease and a description of how Social Security evaluates the disease during its adjudication process for disability claims.[110][111]
Research[edit]
Umbilical cord blood transplant[edit]
While umbilical cord blood transplant can potentially cure the condition, a suitable donor is available in only 10% of people.[112] About 7% of people also die as a result of the procedure and graft versus host disease may occur.[112]
Gene therapy[edit]
In 2001, it was reported that sickle cell disease had been successfully treated in mice using gene therapy.[113][114] The researchers used a viral vector to make the mice—which have essentially the same defect that causes human sickle cell disease—express production of fetal haemoglobin (HbF), which an individual normally ceases to produce shortly after birth. In humans, using hydroxyurea to stimulate the production of HbF has been known to temporarily alleviate sickle cell disease symptoms. The researchers demonstrated that this gene therapy method is a more permanent way to increase therapeutic HbF production.[115]
Phase 1 clinical trials of gene therapy for sickle cell disease in humans were started in 2014. The clinical trials will assess the safety and initial evidence for efficacy of an autologous transplant of lentiviral vector-modified bone marrow for adults with severe sickle cell disease.[116][117] As of 2016, however, no randomized controlled trials have been reported.[118] A case report for the first person treated was published in March 2017.[119]
Notes[edit]
Jump up ^ Historic numbering put this glutamic acid residue at position 6 due to skipping the methionine (M/Met) start codon in protein amino acid position numbering. Current nomenclature calls for counting the methionine as the first amino acid, resulting in the glutamic acid residue falling at position 7. Many references still refer to position 6 and both should likely be referenced for clarity.
References[edit]
^ Jump up to: a b c d e "What Are the Signs and Symptoms of Sickle Cell Disease?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.
^ Jump up to: a b c d e f g h i j "What Is Sickle Cell Disease?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 6 March 2016. Retrieved 8 March 2016.
^ Jump up to: a b c "What Causes Sickle Cell Disease?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 24 March 2016. Retrieved 8 March 2016.
^ Jump up to: a b c "How Is Sickle Cell Disease Diagnosed?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.
^ Jump up to: a b c d "Sickle-cell disease and other haemoglobin disorders Fact sheet N°308". January 2011. Archived from the original on 9 March 2016. Retrieved 8 March 2016.
^ Jump up to: a b c d "How Is Sickle Cell Disease Treated?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.
^ Jump up to: a b GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577  . PMID 27733282.
^ Jump up to: a b c GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903  . PMID 27733281.
Jump up ^ "Learning About Sickle Cell Disease". National Human Genome Research Institute. May 9, 2016. Archived from the original on January 4, 2017. Retrieved January 23, 2017.
Jump up ^ Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 386 (9995): 743–800. doi:10.1016/s0140-6736(15)60692-4. PMC 4561509  . PMID 26063472.
Jump up ^ Rees, DC; Williams, TN; Gladwin, MT (11 December 2010). "Sickle-cell disease". Lancet. 376 (9757): 2018–31. doi:10.1016/s0140-6736(10)61029-x. PMID 21131035.
Jump up ^ Elzouki, Abdelaziz Y. (2012). Textbook of clinical pediatrics (2 ed.). Berlin: Springer. p. 2950. ISBN 9783642022012.
^ Jump up to: a b c Savitt TL, Goldberg MF (Jan 1989). "Herrick's 1910 case report of sickle cell anemia. The rest of the story". JAMA. 261 (2): 266–71. doi:10.1001/jama.261.2.266. PMID 2642320.
^ Jump up to: a b c d e f g h i j Serjeant GR (Dec 2010). "One hundred years of sickle cell disease". British Journal of Haematology. 151 (5): 425–9. doi:10.1111/j.1365-2141.2010.08419.x. PMID 20955412. Archived from the original on 2014-11-16.
^ Jump up to: a b National Libray of Medicine. URL = ghr.nlm.nih.gov/condition/sickle-cell-disease
^ Jump up to: a b Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J (Sep 10, 2014). "Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members". JAMA. 312 (10): 1033–48. doi:10.1001/jama.2014.10517. PMID 25203083. Archived from the original on 2014-11-17.
Jump up ^ "BestBets: How long should an average sickle cell crisis last?". Archived from the original on 2010-06-17. Retrieved 2010-11-27.
Jump up ^ Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; Aster, Jon (2009-05-28). Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Expert Consult – Online (Robbins Pathology) (Kindle Locations 33498-33499). Elsevier Health. Kindle Edition.
Jump up ^ Olujohungbe A, Burnett AL (2013). "How I manage priapism due to sickle cell disease". British Journal of Haematology. 160 (6): 754–65. doi:10.1111/bjh.12199. PMID 23293942.
^ Jump up to: a b Glassberg J (August 2011). "Evidence-based management of sickle cell disease in the emergency department". Emergency Medicine Practice. 13 (8): 1–20; quiz 20. PMID 22164362.
^ Jump up to: a b Anie, Kofi A.; Green, John (2015-05-08). "Psychological therapies for sickle cell disease and pain". The Cochrane Database of Systematic Reviews (5): CD001916. doi:10.1002/14651858.CD001916.pub3. ISSN 1469-493X. PMID 25966336.
Jump up ^ Pearson HA (Aug 1977). "Sickle cell anemia and severe infections due to encapsulated bacteria" (Free full text). J Infect Dis. 136 Suppl: S25–30. doi:10.1093/infdis/136.Supplement.S25. ISSN 0022-1899. PMID 330779. Archived from the original on 2016-05-27.
Jump up ^ Wong WY, Powars DR, Chan L, Hiti A, Johnson C, Overturf G (Mar 1992). "Polysaccharide encapsulated bacterial infection in sickle cell anaemia: a thirty year epidemiologic experience". Am J Hematol. 39 (3): 176–82. doi:10.1002/ajh.2830390305. PMID 1546714.
Jump up ^ Khatib R, Rabah R, Sarnaik SA (January 2009). "The spleen in the sickling disorders: an update". Pediatric Radiology. 39 (1): 17–22. doi:10.1007/s00247-008-1049-9. PMID 19002450.
^ Jump up to: a b Glassberg, J (August 2011). "Evidence-based management of sickle cell disease in the emergency department". Emergency medicine practice. 13 (8): 1–20; quiz 20. PMID 22164362.
Jump up ^ Mekontso Dessap A, Leon R, Habibi A, Nzouakou R, Roudot-Thoraval F, Adnot S, Godeau B, Galacteros F, Brun-Buisson C, Brochard L, Maitre B (2008). "Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease". Am. J. Respir. Crit. Care Med. 177 (6): 646–53. doi:10.1164/rccm.200710-1606OC. PMID 18174543.
Jump up ^ Paul RN, Castro OL, Aggarwal A, Oneal PA (2011). "Acute chest syndrome: sickle cell disease". Eur. J. Haematol. 87 (3): 191–207. doi:10.1111/j.1600-0609.2011.01647.x. PMID 21615795.
Jump up ^ Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; Aster, Jon (2009-05-28). Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Expert Consult – Online (Robbins Pathology) (Kindle Location 33329). Elsevier Health. Kindle Edition.
Jump up ^ Slavov SN, Kashima S, Pinto AC, Covas DT (August 2011). "Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions". FEMS Immunology and Medical Microbiology. 62 (3): 247–62. doi:10.1111/j.1574-695X.2011.00819.x. PMID 21585562.
Jump up ^ Balgir RS (March 2012). "Community expansion and gene geography of sickle cell trait and G6PD deficiency, and natural selection against malaria: experience from tribal land of India". Cardiovascular & Hematological Agents in Medicinal Chemistry. 10 (1): 3–13. doi:10.2174/187152512799201190. PMID 22264009.
Jump up ^ Jadavji T, Prober CG (April 1985). "Dactylitis in a child with sickle cell trait". Can Med Assoc J. 132 (7): 814–5. ISSN 0008-4409. PMC 1345873  . PMID 3978504.
Jump up ^ Worrall VT, Butera V (1976). "Sickle-cell dactylitis". J Bone Joint Surg Am. 58 (8): 1161–3. PMID 1002763. Archived from the original on 2016-09-23.
Jump up ^ Miller ST (May 2011). "How I treat acute chest syndrome in children with sickle cell disease". Blood. 117 (20): 5297–305. doi:10.1182/blood-2010-11-261834. PMID 21406723.
Jump up ^ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. p. 847. ISBN 0-7216-2921-0.
Jump up ^ Reference, Genetics Home. "sickle cell disease". Genetics Home Reference. Archived from the original on 2016-05-15. Retrieved 2016-05-07.
Jump up ^ Green NS, Fabry ME, Kaptue-Noche L, Nagel RL (Oct 1993). "Senegal haplotype is associated with higher HbF than Benin and Cameroon haplotypes in African children with sickle cell anemia". Am. J. Hematol. 44 (2): 145–6. doi:10.1002/ajh.2830440214. ISSN 0361-8609. PMID 7505527.
Jump up ^ Suzanne Clancy (2008). "Genetic mutation". Nature Education. 1 (1): 187.
Jump up ^ Marie-Hélène Odièvre, Emmanuelle Verger, Ana Cristina Silva-Pinto, Jacques Elion. "Pathophysiological insights in sickle cell disease". Indian Journal of Medical Research. 134 (4): 532–537. PMC 3237253  . CS1 maint: Multiple names: authors list (link)
Jump up ^ Allison AC (October 2009). "Genetic control of resistance to human malaria". Current Opinion in Immunology. 21 (5): 499–505. doi:10.1016/j.coi.2009.04.001. PMID 19442502.
Jump up ^ Kwiatkowski DP (Aug 2005). "How Malaria Has Affected the Human Genome and What Human Genetics Can Teach Us about Malaria". Am. J. Hum. Genet. 77 (2): 171–92. doi:10.1086/432519. ISSN 0002-9297. PMC 1224522  . PMID 16001361.
Jump up ^ Ponçon N, Toty C, L'Ambert G, Le Goff G, Brengues C, Schaffner F, Fontenille D (2007). "Biology and dynamics of potential malaria vectors in Southern France". Malar. J. 6 (1): 18. doi:10.1186/1475-2875-6-18. PMC 1808464  . PMID 17313664.
Jump up ^ Lesi FE, Bassey EE (July 1972). "Family study in sickle cell disease in Nigeria". J Biosoc Sci. 4 (3): 307–13. doi:10.1017/S0021932000008622. PMID 5041262.
Jump up ^ "How Does Sickle Cell Cause Disease?". Archived from the original on 2010-09-23. Retrieved 2010-11-27.
Jump up ^ "Sickle Cell Anemia: eMedicine Emergency Medicine". Archived from the original on 2010-12-04. Retrieved 2010-11-27.
Jump up ^ Clarke GM, Higgins TN (August 2000). "Laboratory investigation of haemoglobinopathies and thalassemias: review and update". Clin. Chem. 46 (8 Pt 2): 1284–90. PMID 10926923. Archived from the original on 2008-03-20.
Jump up ^ "BestBets: Does routine urinalysis and chest radiography detect occult bacterial infection in sickle cell patients presenting to the accident and emergency department with painful crisis?". Archived from the original on 2010-06-17. Retrieved 2010-11-27.
Jump up ^ Lee, C., Davies, S.,& Dezatoux, C. (2000). Neonatal Screening for sickle cell disease. The Cochrane Collaboration. John Wiley & Sons, Ltd.
Jump up ^ Commissioner, Office of the (7 July 2017). "Press Announcements – FDA approves new treatment for sickle cell disease". www.fda.gov. Archived from the original on 10 July 2017. Retrieved 10 July 2017.
Jump up ^ "Evidence-Based Management of Sickle Cell Disease" (PDF). 2014. Retrieved November 16, 2017. twice-daily prophylactic penicillin beginning in early infancy and continuing through at least age 5
Jump up ^ Dixit, R (February 16, 2016). "Folate supplementation in people with sickle cell disease". Retrieved November 16, 2017.
Jump up ^ Oniyangi O, Omari AA (2006). Oniyangi, Oluseyi, ed. "Malaria chemoprophylaxis in sickle cell disease". Cochrane Database of Systematic Reviews. 13 (4): CD003489. doi:10.1002/14651858.CD003489.pub2. PMID 17054173.
Jump up ^ Aldrich TK, Nagel RL (1998). "Pulmonary Complications of Sickle Cell Disease.". In Reynolds HY, Bone RC, Dantzker DR, George RB, Matthay RA. Pulmonary and Critical Care Medicine (6th ed.). St. Louis: Mosby. pp. 1–10. ISBN 0-8151-1371-4.
Jump up ^ Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (May 1995). "Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia". N. Engl. J. Med. 332 (20): 1317–22. doi:10.1056/NEJM199505183322001. ISSN 0028-4793. PMID 7715639.
Jump up ^ Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M (April 2003). "Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment". JAMA. 289 (13): 1645–51. doi:10.1001/jama.289.13.1645. PMID 12672732. Archived from the original on 2008-03-16.
Jump up ^ Platt OS (Mar 2008). "Hydroxyurea for the treatment of sickle cell anemia". N. Engl. J. Med. 358 (13): 1362–9. doi:10.1056/NEJMct0708272. PMID 18367739.
Jump up ^ Drasar E, Igbineweka N, Vasavda N, Free M, Awogbade M, Allman M, Mijovic A, Thein SL (March 2011). "Blood transfusion usage among adults with sickle cell disease – a single institution experience over ten years". Br. J. Haematol. 152 (6): 766–70. doi:10.1111/j.1365-2141.2010.08451.x. PMID 21275951.
Jump up ^ Gyang E, Yeom K, Hoppe C, Partap S, Jeng M (January 2011). "Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease". Am. J. Hematol. 86 (1): 104–6. doi:10.1002/ajh.21901. PMID 21117059.
Jump up ^ Mirre E, Brousse V, Berteloot L, Lambot-Juhan K, Verlhac S, Boulat C, Dumont MD, Lenoir G, de Montalembert M (March 2010). "Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease". Eur. J. Haematol. 84 (3): 259–65. doi:10.1111/j.1600-0609.2009.01379.x. PMID 19912310.
Jump up ^ Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernaudin F, Matthews DC, Storb R, Sullivan KM (August 1996). "Bone marrow transplantation for sickle cell disease". N. Engl. J. Med. 335 (6): 369–76. doi:10.1056/NEJM199608083350601. PMC 1029450  . PMID 8663884.
^ Jump up to: a b c d Martí-Carvajal, Arturo J.; Solà, Ivan; Agreda-Pérez, Luis H. (2016-08-09). "Treatment for avascular necrosis of bone in people with sickle cell disease". The Cochrane Database of Systematic Reviews (8): CD004344. doi:10.1002/14651858.CD004344.pub6. ISSN 1469-493X. PMID 27502327.
Jump up ^ Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; Aster, Jon (2009-05-28). Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Expert Consult – Online (Robbins Pathology) (Kindle Locations 33530-33531). Elsevier Health. Kindle Edition.
Jump up ^ Wierenga KJ, Hambleton IR, Lewis NA (2001). "Survival estimates for patients with homozygous sickle-cell disease in Jamaica: A clinic-based population study". Lancet. 357 (9257): 680–683. doi:10.1016/s0140-6736(00)04132-5. PMID 11247552.
Jump up ^ Costa, Fernando Ferreira; Conran, Nicola (2016). Sickle Cell Anemia: From Basic Science to Clinical Practice. Springer. p. 35. ISBN 9783319067131. Retrieved 8 May 2016.
Jump up ^ Kavanagh PL, Sprinz PG, Vinci SR, Bauchner H, Wang CJ (2011). "Management of children with sickle cell disease: a comprehensive review of the literature". Pediatrics. 128 (6): e1552–74. doi:10.1542/peds.2010-3686. PMID 22123880. Archived from the original on 2016-03-04.
Jump up ^ Adams RJ, Ohene-Frempong K, Wang W (2001). "Sickle cell and the brain". Hematology Am Soc Hematol Educ Program. 2001 (1): 31–46. doi:10.1182/asheducation-2001.1.31. PMID 11722977. Archived from the original on 2011-07-24.
Jump up ^ Adams RJ (November 2007). "Big strokes in small persons". Arch. Neurol. 64 (11): 1567–74. doi:10.1001/archneur.64.11.1567. PMID 17998439. Archived from the original on 2011-07-25.
Jump up ^ Kenny MW, George AJ, Stuart J (July 1980). "Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism". Journal of Clinical Pathology. 33 (7): 622–5. doi:10.1136/jcp.33.7.622. PMC 1146172  . PMID 7430367. Retrieved 2011-03-23.
Jump up ^ Chrouser KL, Ajiboye OB, Oyetunji TA, Chang DC (April 2011). "Priapism in the United States: the changing role of sickle cell disease". American Journal of Surgery. 201 (4): 468–74. doi:10.1016/j.amjsurg.2010.03.017. PMID 21421100.
Jump up ^ Almeida A, Roberts I (May 2005). "Bone involvement in sickle cell disease". Br. J. Haematol. 129 (4): 482–90. doi:10.1111/j.1365-2141.2005.05476.x. PMID 15877730.
Jump up ^ Rudge FW (1991). "Hyperbaric oxygen therapy in the treatment of sickle cell leg ulcers". J. Hyperbaric Med. 6 (1): 1–4. Retrieved 2011-03-23.
Jump up ^ Elagouz M, Jyothi S, Gupta B, Sivaprasad S (July 2010). "Sickle cell disease and the eye: old and new concepts". Survey of Ophthalmology. 55 (4): 359–77. doi:10.1016/j.survophthal.2009.11.004. PMID 20452638. Retrieved 2011-03-23.
Jump up ^ Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD (Jan 2008). "Daily assessment of pain in adults with sickle cell disease". Annals of Internal Medicine. 148 (2): 94–101. doi:10.7326/0003-4819-148-2-200801150-00004. ISSN 0003-4819. PMID 18195334.
Jump up ^ Caughey MC, Poole C, Ataga KI, Hinderliter AL (9 April 2015). "Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review". British Journal of Haematology. 170: 416–424. doi:10.1111/bjh.13447. PMID 25854714.
Jump up ^ Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, Johnson C (Oct 1991). "Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality". Annals of Internal Medicine. 115 (8): 614–20. doi:10.7326/0003-4819-115-8-614. ISSN 0003-4819. PMID 1892333.
Jump up ^ Weatherall DJ, Clegg JB (2001). "Inherited haemoglobin disorders: an increasing global health problem". Bull. World Health Organ. 79 (8): 704–12. PMC 2566499  . PMID 11545326.
Jump up ^ Roberts I, de Montalembert M (July 2007). "Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe". Haematologica. 92 (7): 865–71. doi:10.3324/haematol.11474. PMID 17606434. Archived from the original on 2010-12-05.
Jump up ^ Wellems TE, Hayton K, Fairhurst RM (September 2009). "The impact of malaria parasitism: from corpuscles to communities". J. Clin. Invest. 119 (9): 2496–505. doi:10.1172/JCI38307. PMC 2735907  . PMID 19729847. Archived from the original on 2011-06-15.
Jump up ^ National Libray of Medicine. URL = https://ghr.nlm.nih.gov/condition/sickle-cell-disease#statistics Archived 2016-05-15 at the Wayback Machine.
Jump up ^ WHO. "Sickle-cell anaemia – Report by the Secretariat" (PDF). Archived (PDF) from the original on 2011-01-04. Retrieved 2010-11-27.
Jump up ^ Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, Nahlen BL, Lal AA, Udhayakumar V (2002). "Protective effects of the sickle cell gene against malaria morbidity and mortality". Lancet. 359 (9314): 1311–2. doi:10.1016/S0140-6736(02)08273-9. PMID 11965279.
Jump up ^ National Heart, Lung and Blood Institute. "Sickle cell anemia, key points". Archived from the original on 2010-12-02. Retrieved 2010-11-27.
Jump up ^ "September is Sickle Cell Awareness Month". CDC. Archived from the original on 27 September 2010. Retrieved 6 February 2011.
Jump up ^ "Sickle Cell Disease: Data & Statistics". Centers for Disease Control and Prevention. 16 September 2011. Archived from the original on 31 October 2011. Retrieved 8 November 2011.
Jump up ^ "Disorder Name: Sickle Cell Disease". New Born Screening. Archived from the original on 28 September 2016. Retrieved 11 October 2016.
Jump up ^ "Sickle Cell Patients Endure Discrimination, Poor Care And Shortened Lives". NPR.org. Retrieved 12 November 2017.
Jump up ^ Bardakdjian J, Wajcman H (September 2004). "[Epidemiology of sickle cell anemia]". Rev Prat (in French). 54 (14): 1531–3. PMID 15558961.
Jump up ^ Thuret, I; Sarles, J; Merono, F; Suzineau, E; Collomb, J; Lena-Russo, D; Levy, N; Bardakdjian, J; Badens, C (June 2010). "Neonatal screening for sickle cell disease in France: evaluation of the selective process". Journal of clinical pathology. 63 (6): 548–51. doi:10.1136/jcp.2009.068874. PMID 20498028.
Jump up ^ "Inheriting sickle cell anaemia – Live Well – NHS Choices". www.nhs.uk. Archived from the original on 2014-12-02.
Jump up ^ "Sickle cell anaemia – NHS Choices". www.nhs.uk. Archived from the original on 2011-12-13.
Jump up ^ "Who is offered screening and when?". screening.nhs.uk. Archived from the original on 2014-12-31.
Jump up ^ "Give Blood – Resources – Sickle Cell and Blood Donation". Give Blood. Archived from the original on 2014-12-31.
Jump up ^ "Why is Blood from Afro-Caribbean Donors Special?". sicklecellsociety.org. Archived from the original on 2014-12-30.
Jump up ^ Jastaniah W (2011). "Epidemiology of sickle cell disease in Saudi Arabia". Annals of Saudi Medicine. 31 (3): 289–93. doi:10.4103/0256-4947.81540. PMC 3119971  . PMID 21623060.
Jump up ^ Memish ZA, Saeedi MY (2011). "Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia". Annals of Saudi Medicine. 31 (3): 229–35. doi:10.4103/0256-4947.81527. PMC 3119961  . PMID 21623050.
Jump up ^ Al Arrayed, Sheikha (1995). "Features of sickle-cell disease in Bahrain". Eastern Mediterranean Health Journal. 1 (1). Archived from the original on 2016-10-08.
Jump up ^ Al Arrayed, S; Al Hajeri, A (2010). "Public awareness of sickle cell disease in Bahrain". Annals of Saudi medicine. 30 (4): 284–8. doi:10.4103/0256-4947.65256. PMC 2931779  . PMID 20622345.
Jump up ^ "Sickle Cell Anemia". www.hematology.org. 2014-12-16. Archived from the original on 2017-06-25. Retrieved 2017-05-01.
Jump up ^ Awasthy N, Aggarwal KC, Goyal PC, Prasad MS, Saluja S, Sharma M (2008). "Sickle cell disease: Experience of a tertiary care center in a nonendemic area". Annals of Tropical Medicine and Public Health. 1 (1): 1–4. doi:10.4103/1755-6783.43069.
Jump up ^ Author, No. "Life with sickle cell – Nation – Nepali Times". Archived from the original on 2015-06-24.
Jump up ^ Asnani MR, McCaw-Binns AM, Reid ME (2011). "Excess Risk of Maternal Death from Sickle Cell Disease in Jamaica: 1998–2007". PLoS ONE. 6 (10): e26281. doi:10.1371/journal.pone.0026281. PMC 3200316  . PMID 22039456.
Jump up ^ Lebby R (1846). "Case of absence of the spleen". Southern J of Med Pharmacol. 1: 481–3.
^ Jump up to: a b c Ballas SK, Gupta K, Adams-Graves P (Nov 1, 2012). "Sickle cell pain: a critical reappraisal". Blood. 120 (18): 3647–56. doi:10.1182/blood-2012-04-383430. PMID 22923496. Archived from the original on 2014-11-17.
Jump up ^ Herrick JB (1910). "Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia". Arch. Intern. Med. 6 (5): 517–521. doi:10.1001/archinte.1910.00050330050003. PMC 2588723  . Archived from the original on 2010-11-19. ; reprinted as Herrick JB (2001). "Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910". The Yale Journal of Biology and Medicine. 74 (3): 179–84. PMC 2588723  . PMID 11501714.
Jump up ^ Washburn, R.E. (1911). "Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia". The Virginia Medical Semi-Monthly. 15 (21): 490–493.
Jump up ^ "UVa Hospital Celebrating 100 Years". University of Virginia. Archived from the original on 31 January 2015. Retrieved 28 January 2015.
Jump up ^ Mason VR (1922). "Sickle cell anemia". JAMA. 79 (16): 1318–1320. doi:10.1001/jama.1922.02640160038012. Reprinted in PMID 3900438
Jump up ^ Pauling L, Itano HA (1949). "Sickle cell anemia, a molecular disease". Science. 110 (2865): 543–548. doi:10.1126/science.110.2865.543. PMID 15395398.
Jump up ^ "Foster, Gloria". Facts On File History Database. Archived from the original on 2016-03-05. Retrieved 2015-02-25.
Jump up ^ Richard-Lenoble, D; Toublanc, JE; Zinsou, RD; Kombila, M; Carme, B (1980). "Résultats de l'étude systématique de la drépanocytose par électrophorèse de l'hémoglobine chez 1 500 Gabonais" [Results of a systematic study of drepanocytosis in 1,500 Gabonese using hemoglobin electrophoresis]. Bulletin de la Societe de pathologie exotique et de ses filiales (in French). 73 (2): 200–6. PMID 7460122.
Jump up ^ Policy, SSA, Office of Disability. "Social Security Ruling: SSR 2017-3p". www.ssa.gov. Retrieved 2018-01-15.
Jump up ^ "Federal Register, Volume 82 Issue 178 (Friday, September 15, 2017)". www.gpo.gov. Retrieved 2018-01-15.
^ Jump up to: a b Kassim, AA; Sharma, D (December 2017). "Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape". Hematology/oncology and stem cell therapy. 10 (4): 259–266. doi:10.1016/j.hemonc.2017.05.008. PMID 28641096.
Jump up ^ Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P (2001). "Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy". Science. 294 (5550): 2368–71. doi:10.1126/science.1065806. PMID 11743206.
Jump up ^ Wilson, Jennifer Fisher (18 March 2002). "Murine Gene Therapy Corrects Symptoms of Sickle Cell Disease". The Scientist – Magazine of the Life Sciences. Retrieved 17 December 2014.
Jump up ^ St. Jude Children's Research Hospital (4 December 2008). "Gene Therapy Corrects Sickle Cell Disease In Laboratory Study". ScienceDaily. Archived from the original on 13 December 2014. Retrieved 17 December 2014.
Jump up ^ (15 December 2014) Stem Cell Gene Therapy for Sickle Cell Disease, ClinicalTrials.gov Identifier: NCT02247843 Archived 2015-09-03 at the Wayback Machine. ClinicalTrials.gov, U.S. National Institutes of Health, Retrieved 17 December 2014
Jump up ^ (15 December 2014) Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease; ClinicalTrials.gov Identifier: NCT00012545 Archived 2014-12-17 at the Wayback Machine. ClinicalTrials.gov, U.S. National Institutes of Health, Retrieved 17 December 2014
Jump up ^ Olowoyeye, A; Okwundu, CI (14 November 2016). "Gene therapy for sickle cell disease". The Cochrane Database of Systematic Reviews. 11: CD007652. doi:10.1002/14651858.CD007652.pub5. PMID 27841932.
Jump up ^ Ribeil, Jean-Antoine; Hacein-Bey-Abina, Salima; Payen, Emmanuel; Magnani, Alessandra; Semeraro, Michaela; Magrin, Elisa; Caccavelli, Laure; Neven, Benedicte; Bourget, Philippe; El Nemer, Wassim; Bartolucci, Pablo; Weber, Leslie; Puy, Hervé; Meritet, Jean-François; Grevent, David; Beuzard, Yves; Chrétien, Stany; Lefebvre, Thibaud; Ross, Robert W.; Negre, Olivier; Veres, Gabor; Sandler, Laura; Soni, Sandeep; de Montalembert, Mariane; Blanche, Stéphane; Leboulch, Philippe; Cavazzana, Marina (2 March 2017). "Gene Therapy in a Patient with Sickle Cell Disease". New England Journal of Medicine. 376 (9): 848–855. doi:10.1056/NEJMoa1609677.
Further reading[edit]
Library resources about
Sickle cell disease
Resources in your library
Resources in other libraries
Brown, Robert T., ed. (2006). Comprehensive handbook of childhood cancer and sickle cell disease: a biopsychosocial approach. Oxford University Press. ISBN 978-0-19-516985-0.
Hill, Shirley A. (2003). Managing Sickle Cell Disease in Low-Income Families. Temple University Press. ISBN 978-1-59213-195-2.
Serjeant, Graham R.; Beryl E. (2001). Sickle Cell Disease. Oxford University Press. ISBN 978-0-19-263036-0.
Tapper, Melbourne (1999). In the blood: sickle cell anemia and the politics of race. University of Pennsylvania Press. ISBN 978-0-8122-3471-8.
External links[edit]
Classification
D
ICD-10: D57
ICD-9-CM: 282.6
OMIM: 603903
DiseasesDB: 12069
External resources
MedlinePlus: 000527
eMedicine: med/2126 oph/490 ped/2096 emerg/26 emerg/406
GeneReviews: Sickle Cell Disease
Orphanet: 232
Wikimedia Commons has media related to Sickle-cell anemia.
Sickle cell at Curlie (based on DMOZ)
Sickle Cell Anaemia OER Project
show
v
t
e
Diseases of red blood cells (D50–69,74, 280–287)
↑
Polycythemia
Polycythemia vera
↓
Anemia
Nutritional
Micro-: Iron-deficiency anemia
Plummer–Vinson syndrome
Macro-: Megaloblastic anemia
Pernicious anemia
Hemolytic
(mostly normo-)
Hereditary
enzymopathy: G6PD
glycolysis
PK
TI
HK
hemoglobinopathy: Thalassemia
alpha
beta
delta
Sickle-cell disease/trait
HPFH
membrane: Hereditary spherocytosis
Minkowski–Chauffard syndrome
Hereditary elliptocytosis
Southeast Asian ovalocytosis
Hereditary stomatocytosis
Acquired
Autoimmune
WAHA
CAD
PCH
membrane
PNH
MAHA
TM
HUS
Drug-induced autoimmune
Drug-induced nonautoimmune
Hemolytic disease of the newborn
Aplastic
(mostly normo-)
Hereditary: Fanconi anemia
Diamond–Blackfan anemia
Acquired: PRCA
Sideroblastic anemia
Myelophthisic
Blood tests
MCV
Normocytic
Microcytic
Macrocytic
MCHC
Normochromic
Hypochromic
Other
Methemoglobinemia
Sulfhemoglobinemia
Reticulocytopenia
show
v
t
e
Medicine
Outline
History
Specialties
and
subspecialties
Surgery
Cardiac surgery
Cardiothoracic surgery
Colorectal surgery
Eye surgery
General surgery
Neurosurgery
Oral and maxillofacial surgery
Orthopedic surgery
Hand surgery
Otolaryngology (ENT)
Pediatric surgery
Plastic surgery
Reproductive surgery
Surgical oncology
Thoracic surgery
Transplant surgery
Trauma surgery
Urology
Andrology
Vascular surgery
Internal medicine
Allergy / Immunology
Angiology
Cardiology
Endocrinology
Gastroenterology
Hepatology
Geriatrics
Hematology
Hospital medicine
Infectious disease
Nephrology
Oncology
Pulmonology
Rheumatology
Obstetrics and gynaecology
Gynaecology
Gynecologic oncology
Maternal–fetal medicine
Obstetrics
Reproductive endocrinology and infertility
Urogynecology
Diagnostic
Radiology
Interventional radiology
Nuclear medicine
Pathology
Anatomical pathology
Clinical pathology
Clinical chemistry
Clinical immunology
Cytopathology
Medical microbiology
Transfusion medicine
Other specialties
Addiction medicine
Adolescent medicine
Anesthesiology
Dermatology
Disaster medicine
Diving medicine
Emergency medicine
Mass-gathering medicine
Family medicine
General practice
Hospital medicine
Intensive-care medicine
Medical genetics
Neurology
Clinical neurophysiology
Occupational medicine
Ophthalmology
Oral medicine
Pain management
Palliative care
Pediatrics
Neonatology
Physical medicine and rehabilitation (PM&R)
Preventive medicine
Psychiatry
Public health
Radiation oncology
Reproductive medicine
Sexual medicine
Sleep medicine
Sports medicine
Transplantation medicine
Tropical medicine
Travel medicine
Venereology
Medical education
Medical school
Bachelor of Medicine, Bachelor of Surgery
Bachelor of Medical Sciences
Master of Medicine
Master of Surgery
Doctor of Medicine
Doctor of Osteopathic Medicine
MD–PhD
Related topics
Alternative medicine
Allied health
Dentistry
Podiatry
Physiotherapy
Nanomedicine
Molecular oncology
Personalized medicine
Traditional medicine
Veterinary medicine
Physician
Chief physician
History of medicine
Book
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sickle_cell_disease&oldid=853377429"
Categories:
Autosomal recessive disorders
Chronic pain syndromes
Hereditary hemolytic anemias
Health in Africa
Hematopathology
Disorders of globin and globulin proteins
Sickle-cell disease
Hidden categories:
CS1 maint: Multiple names: authors list
Webarchive template wayback links
CS1 French-language sources (fr)
Use British English from November 2010
Infobox medical condition (new)
All articles with unsourced statements
Articles with unsourced statements from May 2016
Articles with unsourced statements from April 2015
Articles with Curlie links
RTT
RTTID
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
বাংলা
Български
Bosanski
Català
Čeština
Deutsch
Eesti
Español
Esperanto
Euskara
فارسی
Français
Gaeilge
Galego
ગુજરાતી
한국어
हिन्दी
Hrvatski
Bahasa Indonesia
Italiano
עברית
ಕನ್ನಡ
Қазақша
Kirundi
Lietuvių
മലയാളം
मराठी
Nederlands
日本語
Norsk nynorsk
ଓଡ଼ିଆ
Piemontèis
Polski
Português
Română
Русский
Simple English
Slovenščina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
Tagalog
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
Tiếng Việt
中文
42 more
Edit links
This page was last edited on 4 August 2018, at 09:59 (UTC).
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

values: mw-page-base noprint

values: mw-head-base noprint

values: firstHeading firstHeading en

values: siteSub noprint

values: mw-jump-link #mw-head

values: mw-jump-link #p-search

value: p

value: th

attrs: colspan style

attrs: href class title

values:
/wiki/Bacterial_infection
mw-redirect
Bacterial infection

values:
/wiki/Diagnostic_method
mw-redirect
Diagnostic method

values:
/wiki/Pain_medication
mw-redirect
Pain medication

values:
/wiki/Blood_disorder
mw-redirect
Blood disorder

values:
/wiki/Developed_world
mw-redirect
Developed world

values: checkbox button toctogglecheckbox toctogglecheckbox display:none

attrs: alt src width height class srcset data-file-width data-file-height

values: Edit section: Splenic sequestration crisis

values:
/wiki/Encapsulated_organisms
mw-redirect
Encapsulated organisms

values:
/wiki/Aplastic_crisis
mw-redirect
Aplastic crisis

values:
/wiki/G6PD_deficiency
mw-redirect
G6PD deficiency

values:
/wiki/Chest_X-ray
mw-redirect
Chest X-ray

values: This claim needs references to reliable sources. (May 2016)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Hematopoietic_ulcers
mw-redirect
Hematopoietic ulcers

values:
/wiki/Autosomal_recessive
mw-redirect
Autosomal recessive

attrs: alt src width height class data-file-width data-file-height

values:
/wiki/Scanning_electron_micrograph
mw-redirect
Scanning electron micrograph

values:
/wiki/Howell-Jolly_body
mw-redirect
Howell-Jolly body

values:
/wiki/Haemoglobin_electrophoresis
mw-redirect
Haemoglobin electrophoresis

values:
/wiki/Haemoglobin_C
mw-redirect
Haemoglobin C

values:
/wiki/Fetal_haemoglobin
mw-redirect
Fetal haemoglobin

values: Transfusion therapy (Sickle-cell disease)

values:
/wiki/Bone_marrow_transplant
mw-redirect
Bone marrow transplant

values:
/wiki/Pain_Medicine
mw-redirect
Pain Medicine

values: This claim needs references to reliable sources. (April 2015)

values:
/wiki/Aseptic_bone_necrosis
mw-redirect
Aseptic bone necrosis

values:
/wiki/Intrauterine_growth_retardation
mw-redirect
Intrauterine growth retardation

values:
/wiki/Right_ventricle
mw-redirect
Right ventricle

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em;

values: Overseas departments and territories of France

values:
/wiki/Adrenal_hyperplasia
mw-redirect
Adrenal hyperplasia

values: Edit section: Umbilical cord blood transplant

values:
/wiki/Umbilical_cord_blood_transplant
mw-redirect
Umbilical cord blood transplant

values:
/wiki/Graft_versus_host_disease
mw-redirect
Graft versus host disease

values:
reflist mw-references-wrap
list-style-type: decimal;

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27733282

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27733281

values: National Human Genome Research Institute

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26063472

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21131035

values:
nofollow
external text
//doi.org/10.1001/jama.261.2.266

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2642320

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20955412

values:
nofollow
external text
//doi.org/10.1001/jama.2014.10517

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25203083

values:
nofollow
external text
//doi.org/10.1111/bjh.12199

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23293942

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22164362

values:
nofollow
external text
//www.worldcat.org/issn/1469-493X

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25966336

values:
nofollow
external text
//www.worldcat.org/issn/0022-1899

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/330779

values:
nofollow
external text
//doi.org/10.1002/ajh.2830390305

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1546714

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19002450

values:
nofollow
external text
//doi.org/10.1164/rccm.200710-1606OC

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18174543

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21615795

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21585562

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22264009

values:
nofollow
external text
//www.worldcat.org/issn/0008-4409

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3978504

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1002763

values:
nofollow
external text
//doi.org/10.1182/blood-2010-11-261834

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21406723

values:
nofollow
external text
//doi.org/10.1002/ajh.2830440214

values:
nofollow
external text
//www.worldcat.org/issn/0361-8609

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7505527

values: Category:CS1 maint: Multiple names: authors list

values:
nofollow
external text
//doi.org/10.1016/j.coi.2009.04.001

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19442502

values:
nofollow
external text
//doi.org/10.1086/432519

values:
nofollow
external text
//www.worldcat.org/issn/0002-9297

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16001361

values:
nofollow
external text
//doi.org/10.1186/1475-2875-6-18

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17313664

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/5041262

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10926923

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17054173

values:
nofollow
external text
//doi.org/10.1056/NEJM199505183322001

values:
nofollow
external text
//www.worldcat.org/issn/0028-4793

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7715639

values:
nofollow
external text
//doi.org/10.1001/jama.289.13.1645

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12672732

values:
nofollow
external text
//doi.org/10.1056/NEJMct0708272

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18367739

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21275951

values:
nofollow
external text
//doi.org/10.1002/ajh.21901

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21117059

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19912310

values:
nofollow
external text
//doi.org/10.1056/NEJM199608083350601

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8663884

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27502327

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11247552

values:
nofollow
external text
//doi.org/10.1542/peds.2010-3686

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22123880

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11722977

values:
nofollow
external text
//doi.org/10.1001/archneur.64.11.1567

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17998439

values:
nofollow
external text
//doi.org/10.1136/jcp.33.7.622

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7430367

values:
/wiki/American_Journal_of_Surgery
mw-redirect
American Journal of Surgery

values:
nofollow
external text
//doi.org/10.1016/j.amjsurg.2010.03.017

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21421100

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15877730

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20452638

values:
nofollow
external text
//www.worldcat.org/issn/0003-4819

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18195334

values:
nofollow
external text
//doi.org/10.1111/bjh.13447

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25854714

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1892333

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11545326

values:
nofollow
external text
//doi.org/10.3324/haematol.11474

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17606434

values:
nofollow
external text
http://www.jci.org/articles/view/38307

values:
nofollow
external text
//doi.org/10.1172/JCI38307

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19729847

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11965279

values: Centers for Disease Control and Prevention

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15558961

values:
nofollow
external text
//doi.org/10.1136/jcp.2009.068874

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20498028

values:
nofollow
external text
http://www.sct.screening.nhs.uk/who

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21623060

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21623050

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20622345

values:
nofollow
external text
//doi.org/10.1371/journal.pone.0026281

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22039456

values:
nofollow
external text
//doi.org/10.1182/blood-2012-04-383430

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22923496

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11501714

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3900438

values:
nofollow
external text
//doi.org/10.1126/science.110.2865.543

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15395398

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7460122

values:
nofollow
external text
//doi.org/10.1016/j.hemonc.2017.05.008

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/28641096

values:
nofollow
external text
//doi.org/10.1126/science.1065806

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11743206

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27841932

values:
nofollow
external text
//doi.org/10.1056/NEJMoa1609677

values: float:right;clear:right;width:auto;margin:0 0 1.0em 1.0em;background:#f9f9f9;border:1px solid #aaa;padding:0.2em;border-spacing:0.4em 0;text-align:center;line-height:1.4em;font-size:88%;text-align:left;

values: International Statistical Classification of Diseases and Related Health Problems

values:
nofollow
external text
https://omim.org/entry/603903

values: width:22em;width:100%; margin:0 0 0.5em 0;

values:
nofollow
external text
http://www.sicklecellanaemia.org

values: Template talk:Diseases of RBCs (page does not exist)

values: ICD-10 Chapter III: Diseases of the blood and blood-forming organs, and certain disorders involving the immune mechanism

values: List of ICD-9 codes 280–289: diseases of the blood and blood-forming organs

values:
/wiki/Pernicious_anemia
mw-redirect
Pernicious anemia

values:
/wiki/Sickle-cell_disease
mw-redirect
Sickle-cell disease

values: Hereditary persistence of fetal hemoglobin

values:
/wiki/Warm_autoimmune_hemolytic_anemia
mw-redirect
Warm autoimmune hemolytic anemia

values: Drug-induced autoimmune hemolytic anemia

values: Drug-induced nonautoimmune hemolytic anemia

values: Mean corpuscular hemoglobin concentration

values: nowraplinks collapsible autocollapse navbox-inner mw-collapsible mw-made-collapsible mw-collapsed

values:
navbox-abovebelow
2
font-weight:bold; text-align:left;

values:
/wiki/Thoracic_surgery
mw-redirect
Thoracic surgery

values: Reproductive endocrinology and infertility

values:
/wiki/Clinical_immunology
mw-redirect
Clinical immunology

values:
/wiki/Mass-gathering_medicine
mw-redirect
Mass-gathering medicine

values:
/wiki/Intensive-care_medicine
mw-redirect
Intensive-care medicine

values:
/wiki/Preventive_medicine
mw-redirect
Preventive medicine

values:
/wiki/Radiation_oncology
mw-redirect
Radiation oncology

values:
/wiki/Transplantation_medicine
mw-redirect
Transplantation medicine

values: Bachelor of Medicine, Bachelor of Surgery

values:
/wiki/Allied_health
mw-redirect
Allied health

values: nowraplinks hlist collapsible autocollapse navbox-inner mw-collapsible mw-made-collapsible mw-collapsed

values: Category:Disorders of globin and globulin proteins

values: Category:Webarchive template wayback links

values: Category:CS1 French-language sources (fr)

values: Category:Use British English from November 2010

values: Category:Infobox medical condition (new)

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from May 2016

values: Category:Articles with unsourced statements from April 2015

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Sickle_cell_disease
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values: فقر الدم المنجلي – Arabic

values: কাস্তে-কোষ ব্যাধি – Bangla

values:
interlanguage-link interwiki-bn
display: none;

values: Сърповидно-клетъчни нарушения – Bulgarian

values:
interlanguage-link interwiki-bg
display: none;

values:
interlanguage-link interwiki-bs
display: none;

values: Anèmia de cèl·lules falciformes – Catalan

values:
interlanguage-link interwiki-ca
display: none;

values:
interlanguage-link interwiki-cs
display: none;

values:
interlanguage-link interwiki-et
display: none;

values:
interlanguage-link interwiki-eo
display: none;

values:
interlanguage-link interwiki-eu
display: none;

values: کم‌خونی داسی‌شکل – Persian

values:
interlanguage-link interwiki-fa
display: none;

values:
interlanguage-link interwiki-ga
display: none;

values:
interlanguage-link interwiki-gl
display: none;

values: સિકલસેલ એનીમિયા રોગ – Gujarati

values:
interlanguage-link interwiki-gu
display: none;

values: 겸형 적혈구 빈혈증 – Korean

values:
interlanguage-link interwiki-ko
display: none;

values: सिकल-सेल रोग – Hindi

values:
interlanguage-link interwiki-hr
display: none;

values:
interlanguage-link interwiki-it
display: none;

values: אנמיה חרמשית – Hebrew

values:
interlanguage-link interwiki-he
display: none;

values: ಕುಡಗೋಲು-ಕಣ ರೋಗ – Kannada

values:
interlanguage-link interwiki-kn
display: none;

values: Орақ тәрізді-клеткалы қаны аздық – Kazakh

values:
interlanguage-link interwiki-kk
display: none;

values:
interlanguage-link interwiki-rn
display: none;

values:
interlanguage-link interwiki-lt
display: none;

values: അരിവാൾ കോശ വിളർച്ച – Malayalam

values:
interlanguage-link interwiki-ml
display: none;

values: सिकलसेल – Marathi

values:
interlanguage-link interwiki-mr
display: none;

values:
interlanguage-link interwiki-nl
display: none;

values:
interlanguage-link interwiki-ja
display: none;

values:
interlanguage-link interwiki-nn
display: none;

values: ସିକ୍ଲ ସେଲ୍ ରୋଗ – Odia

values:
interlanguage-link interwiki-or
display: none;

values:
interlanguage-link interwiki-pms
display: none;

values: Niedokrwistość sierpowatokrwinkowa – Polish

values:
interlanguage-link interwiki-pl
display: none;

values:
interlanguage-link interwiki-ro
display: none;

values: Серповидноклеточная анемия – Russian

values:
interlanguage-link interwiki-simple
display: none;

values:
interlanguage-link interwiki-sl
display: none;

values: Српаста анемија – Serbian

values:
interlanguage-link interwiki-sr
display: none;

values:
interlanguage-link interwiki-sh
display: none;

values:
interlanguage-link interwiki-fi
display: none;

values:
interlanguage-link interwiki-sv
display: none;

values:
interlanguage-link interwiki-tl
display: none;

values: அரிவாள்செல் சோகை – Tamil

values:
interlanguage-link interwiki-ta
display: none;

values: సికిల్ సెల్ వ్యాధి – Telugu

values:
interlanguage-link interwiki-te
display: none;

values: โรคเม็ดเลือดแดงรูปเคียว – Thai

values:
interlanguage-link interwiki-th
display: none;

values:
interlanguage-link interwiki-tr
display: none;

values: Серповидноклітинна анемія – Ukrainian

values:
interlanguage-link interwiki-uk
display: none;

values:
interlanguage-link interwiki-vi
display: none;

values: 鐮刀型紅血球疾病 – Chinese

values: All languages (initial selection from common choices by you and others)

values: /static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x

values: /static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x

values:
suggestions
display: none; font-size: 13px;

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Sickle_cell_disease rootpage-Sickle_cell_disease skin-vector action-view